Provided is an antibody that recognizes a tight junction protein 18.2, a preparation method therefor, and a use thereof.

An agent for preventing, suppressing the progression of symptoms of or the recurrence of, and/or treating hematological cancer, including a protein having a first arm specifically binding to PD-1 and a second arm specifically binding to CD3, such as a PD-1/CD3 bispecific antibody or antibody fragment thereof.

Provided herein are novel isolated, synthetic or recombinant antibodies and fragments thereof specific for factor H, or nucleic acids or vectors encoding such antibodies and fragments. Further provided herein is the use of such antibodies, fragments, nucleic acids or vectors for inhibiting complement activation and treatment of disorders associated with complement activation.

This disclosure provides a multimeric binding molecule, e.g., an IgM, IgM-like, IgA, or IgA-like binding molecule, e.g., an antibody with enhanced selectivity for cells expressing a target antigen at high density, e.g., tumor cells. Enhanced selectivity can be achieved, e.g., through modulation of binding affinity for the target antigen and/or through adjusting avidity via multimeric antigen binding.

The present invention relates to methods of treating a B-cell proliferative disorder by administering an anti-CD20/anti-CD3 bispecific antibody, and methods for reduction of adverse effects in response to the administration of the anti-CD20/anti-CD3 bispecific antibody. The present invention further relates to combination treatment methods of treating a B-cell proliferative disorder.

Multispecific binding molecules (MBMs) comprising at least three antigen binding sites that bind to FGR1c, the GH1 domain of Klotho beta (“KLB”), and the GH2 domain of KLB, pharmaceutical compositions containing the MBMs, methods of using the MBMs and pharmaceutical compositions for treating metabolic diseases, nucleic acids encoding the MBMs, cells engineered to express the MBMs, and methods of producing MBMs.

The present disclosure provides antibodies that bind to the SARS-CoV-2 spike protein, as well as compositions containing the same, and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.

The present invention relates to anti-human OX40L antibodies, new medical uses and methods.

Isolated monoclonal antibodies that bind to human complement component C6 and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic methods for using the antibodies.

Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.